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oRobert Alan Good, MD, PhD, was a uniquely in-
ightful immunologist and physician whose discoveries
nd life’s work distinguished the lineages of lymphocytes
esponsible for cell-mediated and humoral immunity.
r. Good recognized and ﬁrst demonstrated HLA com-
atibility as a key to the success of human allogeneic
arrow transplantations and thereafter made seminal
ontributions to our understanding of the cellular inter-
ctions that contribute to the reconstitution of immunity
nd to the emergence of tolerance. His work directly led
o the use of allogeneic hematopoietic cell transplants to
orrect lethal inherited diseases of the lymphoid and
ematopoietic systems in humans and the potential of
uch transplants in models of autoimmune disease. Dr.
ood died on June 13, 2003, at the age of 81. He had
een active at his work until shortly before his death due
o late complications of cancer.
Dr. Good was born and raised in Crosby, MN. In
944, he graduated from the University of Minnesota.
espite a bout of polio, which weakened his legs, he
ent on to receive his MD and PhD degrees from the
niversity in 1947. After residency training in pediat-
ics and a research fellowship at the Rockefeller Insti-
ute, he joined the faculty at the University of Min-
esota School of Medicine. By 1962, he had attained
he rank of professor in the Departments of Pediatrics
nd Microbiology; he was appointed a Regent’s Pro-
essor at the university in 1969. In 1973, Dr. Good
ssumed the position of president and director of the
loan-Kettering Institute and director of research at
emorial Sloan-Kettering Cancer Center, where he
ostered translational research and radically increased
he proportion of research funded by peer-reviewed
rants. In 1982, he moved to the University of Okla-
oma as head of the cancer program at the Oklahoma
edical Research Foundation. In 1985, he moved to
ecome chairman of the Department of Pediatrics at o
08he University of South Florida and, until 2001, was
hysician-in-chief at the university’s All Children’s
ospital in St. Petersburg; thereafter, he continued
is research as distinguished professor and director of
he Children’s Research Institute.
Dr. Good’s research was initially focused on the role
f plasma cells and antibodies in the immunopathology
f autoimmune encephalitis. Thereafter, he gained ac-
laim for his studies delineating the pathogenesis of the
chwartzman reaction with Lewis Thomas, MD.
In 1962, Dr. Good ﬁrst presented his work on the
hymus and its role in the development of cell-medi-
ted immune responses. His contributions and those
f Jacques Miller, PhD, led to the recognition of
eparate thymus- and bursal-derived lymphoid lin-
ages that, respectively, produce the T cells responsi-
le for cell-mediated immunity and the B cells that
enerate antibodies. His detailed analyses of the
ymph nodes, tonsils, and spleens of thymectomized
ice and bursectomized chickens at different stages of
mbryogenesis characterized the development of each
ineage within the lymphoreticular system. His studies
ith Max Cooper, MD, then deﬁned the stepwise
rogression of the classes of immunoglobulins pro-
uced by B cells during embryogenesis. By comparing
hese ﬁndings in preclinical models with results of his
etailed clinicopathologic analyses of children with
mpaired resistance to speciﬁc types of infections, he
as able to establish a new conceptual framework for
he identiﬁcation and characterization of genetic dis-
rders of immunity. Although he did not coin the
hrase experiments of nature, he repeatedly demon-
trated their potential to enlighten, to instruct, and to
pen doors to new possibilities. His capacity to rec-
gnize natural experiments presented by inherited dis-
rders of immunity, to describe distinctive aberrationsReceived and accepted August 27, 2003
oi:10.1016/S1083-8791(03)00330-6f lymphoid development and functions associated
with each disorder, and to translate clinical and patho-
logic evidence of impaired resistance into new knowl-
edge was unique and unequaled.
Dr. Good’s many contributions in the ﬁeld of
marrow transplantation evolved from this seminal
work. In 1962, the year he ﬁrst identiﬁed the distinc-
tive functions of the thymus in immunity, he demon-
strated the critical importance of the thymus-derived
lymphocytes for skin allograft rejection. He also re-
ported that spleen cells from neonatally thymecto-
mized mice would not induce graft-versus-host dis-
ease (GVHD), thus providing a foundation for
subsequent explorations of T cell–depleted grafts. In
1964, with Yunis, Hilgard, Sjodin, and Martinez, he
also demonstrated that syngeneic spleen cells or iso-
lated thymocytes would reconstitute the immune sys-
tem and reverse wasting in mice thymectomized in the
neonatal period. Early attempts to correct severe com-
bined immunodeﬁciencies (SCID) in children with
fetal thymus or small doses of adult marrow failed to
engraft, failed to reconstitute immune function, or
induced lethal GVHD. In 1968, Dr. Good and his
colleagues were impressed by the prolonged survival
of human skin allografts in hosts matched by mixed
lymphocyte culture (MLC) and existing serologic typing
for HLA reported by Bach and Amos and by Van Rood
and Bernisse. They reasoned that these outcomes resem-
bled those of H-2–compatible skin grafts in mice. Be-
cause their own experiments demonstrated that the use
of H-2–compatible spleen cell transplants prevented fe-
tal GVHD, they hypothesized that histocompatibility
deﬁned by MLC and serologic typing could be used to
identify a compatible sibling donor for a child with
SCID. This marrow transplant was the ﬁrst to achieve
sustained engraftment and successful long-term recon-
stitution of both lymphoid and hematopoietic function
without lethal GVHD. The patient, now a healthy adult,
remains a full chimera to the present day.
In subsequent years, Dr. Good provided critical sup-
port to Bo Dupont, John Hanson, and me in explora-
tions of partially matched, MLC-compatible related
transplants and the initial successful use of marrow from
a histocompatible unrelated donor to correct SCID. His
vision, encouragement, and steadfast support also sus-
tained Yair Reisner and me in the development and
applications of HLA haplotype–disparate parental T
cell–depletedmarrow grafts for the treatment of patients
with SCID and leukemia. Similarly, his pioneering stud-
ies with Ikehara on the use of allogeneic marrow grafts
for the prevention and/or treatment of autoimmune dis-
orders, including nephritis and type 1 diabetes, in genet-
ically susceptible strains of mice provided a strong sci-
entiﬁc framework for the exploration of hematopoietic
cell transplants in the treatment of selected autoimmune
diseases in humans.
In addition to his seminal contributions in devel-
opmental immunobiology, marrow transplantation,
and the biology of human immunodeﬁciency diseases,
Dr. Good has also conducted pioneering research on
the phylogenetic development of the immune system,
the effects of nutrition on autoimmune diseases and
aging, and the effector mechanisms that contribute to
infection-associated immunopathology. Dr. Good’s
energy and enthusiasm are legendary. This energy—
coupled with his keen intellect and his singular capac-
ities to assimilate new knowledge, detect potential
biologic relationships, and formulate testable hypoth-
eses—made him an exceptionally productive investi-
gator. Dr. Good published more than 2000 articles,
edited more than 50 texts, and received 13 honorary
degrees and more than 100 awards, including the
Albert Lasker Award for Clinical Research in 1970,
election to the National Academy of Sciences, and
founding membership in the Institute of Medicine.
He fostered the development of several scientiﬁc so-
cieties and served as president of the American Society
of Clinical Investigators (1968), the American Society
for Experimental Pathology, and the American Asso-
ciation of Immunologists (1975-1976). He also served
on President Nixon’s Cancer Panel.
For those who knew him, he is perhaps most
vividly remembered as a spirited, uniquely engaging
teacher who energized his students and colleagues
alike to explore new ideas, to become fully absorbed in
scientiﬁc inquiry, and to share in the exhilaration of
discovery. One rarely felt more alert than at 5:00 am in
the midst of a meeting with Dr. Good discussing a
paper or grant or planning an experiment, or at sci-
entiﬁc conferences answering probing questions about
your experiments asked by this man in the front row,
who took copious notes and had grasped, often with
disconcerting clarity, both the contents and the po-
tential of your work. Even those who vehemently
disagreed with his hypotheses and interpretations en-
joyed the joust, appreciated the intellectual integrity
of the engagement, and knew that the argument
would be decided on the merits of scientiﬁc evidence
alone. He was also a gifted physician who consistently
focused his work to address the mechanisms and con-
sequences of diseases as presented by patients. His
concern for their welfare galvanized his determination
to develop transplantation and other effective treat-
ments for all children affected with lethal debilitating
disorders of immunity. His recognition of the singular
demands and difﬁculties inherent in clinical research
also encouraged and sustained many young investiga-
tors through rough times in centers throughout the
world. He was a big-spirited man who enjoyed science
and medicine and those engaged in it—a visionary
endlessly intrigued by the order and complexity of
nature; who laughed at the quirks of humankind, in-
cluding his own; who trusted and vigorously espoused
the potential of scientiﬁc research; and who, through
his work, enriched us all.
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